Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Cash from Investing Activities (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of Cash from Investing Activities data on record, last reported at $9.8 million in Q4 2024.

  • For Q4 2024, Cash from Investing Activities rose 150.2% year-over-year to $9.8 million; the TTM value through Dec 2024 reached -$61.7 million, down 590.33%, while the annual FY2025 figure was $4.6 million, 107.39% up from the prior year.
  • Cash from Investing Activities reached $9.8 million in Q4 2024 per SGMT's latest filing, up from $624000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $19.4 million in Q1 2023 and bottomed at -$75.2 million in Q2 2024.